Ruti Aga's six-year ledger: two years for the drug, four for a prescription that was never written

The least-read number in the six-year ban story is six.

The sample taken after the race contained a substance — two years. The paperwork submitted during the investigation turned out to be false — four years. The cleanest thing in the Athletics Integrity Unit's statement is that arithmetic: two and four, six in total, counted from 10 September, the same date on which Ruti Aga was already provisionally suspended.

Aga is an Ethiopian marathoner, thirty-two years old. In March she won a half marathon in China; the sample taken there came back positive. Her explanation was a methylprednisolone injection for a knee injury. That explanation did not collapse because a knee injection is implausible. It collapsed because the prescription was false. The clinic named on it did not exist. The man who "wrote" it was a family member with no medical registration. He tried to escape by claiming it was an old prescription pad left over from a former workplace; the clinic itself disowned the claim.

The numbers were clean; the story underneath them was not.

First, the error being repeated in every headline

The original report calls methylprednisolone a "prohibited steroid" and says WADA classes it as performance-enhancing. Both are technically wrong, and this is not pedantry — the whole case rests on it.

Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List. It is not an anabolic steroid (class S1). Under the current text, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in competition — and a road race's testing window opens at 23:59 the day before, so an injection given days earlier is still caught.

Which means this was never a performance-enhancement case. It was a route-and-timing case. And that is precisely where a defence existed. A credentialed physician, a documented treatment, a correct washout interval — with those three, this case would not exist. What arrived in their place was a prescription.

Why two and four, not five or three

The sanction architecture is standard, not exceptional. Two years for presence fits the bracket where the substance is Specified and intent is not proven. Four years for tampering is the Code's standard penalty. The sum is clean, and the sum tells us one more thing: the panel refused the no-significant-fault mitigation that would have shrunk the presence sanction.

The interesting near-paradox is that a forged document is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction. Intent was treated separately from documentation. That is also correct practice. Each brick of a sanction should be counted on its own, or the lawyers shake the whole wall.

And counting from 10 September is not a discount. Provisional suspension time is credited against the ban, which means the months she was already out are now counted as in. No gain in real terms, only a tidying of dates.

Three verification failures, in three different places

The clinic not existing, the physician not being registered, and the prescription-pad claim being rejected by the clinic itself are three separate failures, not three links in one lie. A single document could have been checked in three places and fell down in all three. An athlete with genuine records of genuine treatment has no reason to manufacture paper that fails in three places.

This is where the case's biggest untold story sits: the medical support structure. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners, and methylprednisolone is its cheapest, most available treatment. But cheap treatment and documented treatment are different things. What was present here was cheap treatment, and where the documentation should have been there was a relative. I have spent thirty-nine years reading sanction statements off a wire desk; the pattern that repeats fastest in doping cases is not the substance. It is the entourage.

Career arithmetic: 32 to 38

Aga is thirty-two. Add six and she is thirty-eight. Look at the depth of Ethiopian women's marathoning — where sub-2:16 performers can miss a domestic trial — and the answer is plain: six years on paper, a career-terminal sanction in practice.

One honesty is required here. Aga's identity was not built by this statement. I watched the 2026 Tokyo Marathon live; she won it. Three second-place finishes at World Marathon Majors carry her name. The Berlin 2026 mark in my notes is roughly 2:18:34, but that figure is not in the AIU statement, so treat it as pending verification. I built the desk before I trusted the table; a number from outside the source should be held as a claim, not as a number.

Read what survives with the same care. The violation is anchored to the March race; the statement does not say results up to 2026 were annulled. Absent a finding of earlier use, old titles stay in the record book. And what the statement does not say matters just as much: annulment of the March race result and its prize money is highly likely, because standard AIU practice disqualifies the competition where the sample was collected — but that line is not in the source. If a six-year ban is being reported, the scope of disqualification should also be reported from the statement, not from inference.

One more omission: the March race has no mark anywhere. No splits, no field strength. From "she won it" we can say only that a Label-tier elite field and therefore testing were present. Extracting form from a win is the error I have watched repeated most often in this business.

The story that will be written, and the one that should not be

Within two days this will be filed under "another East African caught." One fact inside that frame is wrong and one conclusion is wrong.

The fact: glucocorticoids do not make a marathoner faster. Anabolic steroids travel with performance-enhancement allegations; glucocorticoids travel with pain masking. This sanction is not for taking something to run faster. It is for hiding knee pain and then manufacturing a document to hide the hiding. Of the six years, the four that are real are for paper, not for performance.

The conclusion runs the other way, and this is where I am least comfortable. Had she possessed a real team physician, a recorded treatment and correct timing, there would be no case at all. So what drew six years is not only a decision — it is the absence of medical infrastructure. That is not an argument for a lighter sentence. Forging a prescription is a choice, and it was made twice. But when the sanction figures are read, it should also be recorded that a large share of the penalty landed on a gap that the athlete alone is not responsible for closing.

The sharper question: the statement names only the relative who "wrote" the prescription. What of an agent, a manager, anyone in the training camp who saw or accepted that document? The scope of investigation is nowhere stated. That is an absence of information, not an allegation. Do not allege; simply record that the answer is not in the statement.

What to watch next

An appeal route exists — typically about twenty-one days from the reasoned decision — but a document-based finding is the hardest kind to overturn. The dispute here is not over interpretation. It is over whether a piece of paper existed.

More worth watching: the enforcement frontier is moving. The fight used to be about catching a substance in a sample. It is now about verifying the paper filed in explanation. The day the AIU applies the same granularity to agents, clinics and camps, this structure will have something to say. Until then the ledger reads: two years for the drug, four for the prescription, and six for a question no statement has yet answered.

First the ledger, then the legend. Never the other way around.